Loading...
XASXCMP
Market cap30mUSD
Jan 08, Last price  
0.27AUD
1D
-1.85%
1Q
-18.46%
Jan 2017
-69.54%
Name

Compumedics Ltd

Chart & Performance

D1W1MN
XASX:CMP chart
P/E
P/S
0.98
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
3.68%
Revenues
50m
+17.24%
38,499,00038,877,00036,871,00038,582,00038,181,00032,611,00031,265,00027,915,00027,150,00030,841,00033,494,99937,544,00034,417,00037,002,00041,505,00035,069,00035,740,00037,756,00042,408,00049,719,000
Net income
-338k
L-94.48%
-3,898,000-1,595,000123,000756,0002,727,000414,00081,000-2,829,000-1,489,000909,0001,970,0003,273,0001,305,0002,784,0004,016,000-5,838,000998,0001,357,000-6,122,000-338,000
CFO
2m
+3,983.76%
-366,590-1,378,000847,0001,863,0004,568,000454,000-263,0001,376,000409,000686,0002,202,0002,232,000864,000559,0005,136,0005,383,0001,324,0003,287,00048,9992,001,000
Dividend
Nov 23, 20040.0071428571 AUD/sh
Earnings
Feb 26, 2025

Profile

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
IPO date
Dec 21, 2000
Employees
135
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
49,719
17.24%
42,408
12.32%
37,756
5.64%
Cost of revenue
50,531
45,942
37,619
Unusual Expense (Income)
NOPBT
(812)
(3,534)
137
NOPBT Margin
0.36%
Operating Taxes
818
(597)
341
Tax Rate
248.91%
NOPAT
(1,630)
(2,937)
(204)
Net income
(338)
-94.48%
(6,122)
-551.14%
1,357
35.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,752
7,906
6,169
Long-term debt
2,427
2,915
532
Deferred revenue
34
76
145
Other long-term liabilities
36
67
54
Net debt
7,637
6,321
(1,806)
Cash flow
Cash from operating activities
2,001
49
3,287
CAPEX
(313)
(4,408)
(2,985)
Cash from investing activities
(2,987)
(4,408)
(2,985)
Cash from financing activities
(1,490)
(1,005)
1,615
FCF
712
(568)
348
Balance
Cash
1,890
3,797
7,294
Long term investments
652
703
1,213
Excess cash
56
2,380
6,619
Stockholders' equity
18,210
18,291
23,591
Invested Capital
26,802
24,165
23,719
ROIC
ROCE
0.45%
EV
Common stock shares outstanding
177,163
177,163
177,163
Price
0.34
86.11%
0.18
16.13%
0.16
-60.76%
Market cap
59,350
86.11%
31,889
16.13%
27,460
-60.76%
EV
66,987
38,210
25,654
EBITDA
758
(2,521)
1,349
EV/EBITDA
88.37
19.02
Interest
739
652
401
Interest/NOPBT
292.70%